Professional Experience: Auditor at Peat, Marwick, Mitchell & Co. Controller of a small manufacturing company, a division of U S Industries. Director of Business Planning at Esmark, Inc. Position included strategic planning, competitor comparisons, and analysis of potential acquisitions. CFO of a Fortune 500 company, Envirodyne Industries, Inc., which was sold in 1989 for $ 40/share vs $ 1/share (approximately) when I joined the company in 1984. Envirodyne grew threw internal growth and acquisitions. Our management team was skillful and, quite frankly, many variables beyond our control turned out favorably for us. Adjunct professor teaching Accounting I and II, Investments and Personal Finance courses at Benedictine University in Lisle, IL Now semi-retired, actively manage my own portfolio. Tutor math and teach religious education at local schools. My portfolio was devastated during the 2008-09 crisis, but has partially rebounded since then--my portfolio is more conservative these days. I totally ignored the warning signs back then. I am more open now to weighing and considering more extreme scenarios that I would have ignored before the most recent crisis. NOT a stock broker nor in any way registered with the S.E.C. I am strictly a private investor. Earned BS in BA from John Carroll University, Cleveland, OH. Earned Masters in Accounting from Ohio State University in Columbus, OH.
I am a private investor, focused on value investing through balance sheet analysis.
I am not a financial professional nor do I work predominantly in finance.
I am a Business Development professional, working to develop new offerings into strong businesses.
Founded in 1939, Neuberger Berman is an independent, employee-owned investment manager. The firm manages equities, fixed income, private equity and hedge fund portfolios for global institutions, advisors and individuals. With offices in 19 countries, Neuberger Berman’s team is approximately 2,100 professionals and was named by Pensions & Investments as a Best Place to Work in Money Management for 2013, 2014, and 2015. Tenured, stable and long-term in focus, the firm fosters an investment culture of fundamental research and independent thinking. For important disclosures: http://www.nb.com/disclosure-global-communications
RIA & Family Office
Six-time CEO followed by successful strategy and executive-team-performance-improvement consulting business. Semi-retired (not working full time but serve on 2 corporate Boards) and re-balancing my portfolio to dividend growth. Objective is to get 5% from portfolio every year - 3.5 points from dividends and 1.5 points from capital gains. Prefer higher DGR to higher yield, but need about 3% yield on portfolio. "...research revealed some surprising results. Over any longer period, say five to ten years, the companies with the lowest dividend yields and the highest consistent dividend growth were the top performers." Divs should be from companies whose long term history is raising divs faster than inflation. Therefore, over time the 1.5 points from stock sales should diminish to $ zero. The overall portfolio should have 3 buckets of roughly equal proportion: A. 2 to 3% yielders with high DGR (>10% over at least 10 + years - stocks most often come from Consumer Cyclical, Tech, and Industrial sectors) B. stocks which have a much higher than average dividend yield, say 4 to 6%,combined with dividend growth at 6 to 8%/yr over 5 + years. Portfolio B stocks are mostly filled with Utilities, Telecommunications, REITs, and Energy stocks. C. very undervalued stocks which combine a higher than average dividend yield 3 to 4 % with at least a dgr no less than 6%. These stocks don't come from specific sectors because the reasons for undervaluation are company/industry specific headwinds or uncertainties. % needed from sales equals about 1% of portfolio. Anticipating a 6 to 8%/yr long term increase in portfolio value, not counting divs, I expect portfolio value to increase and therefore provide a necessary cushion to achieving planning objectives. Stock prices follow earnings in the long term. Therefore, stock prices should increase at roughly the DGR and vice versa. So, primary focus should be on estimated 5 and 1 year EPS growth, followed by 10, 5,3 and 1 year DGR histories. Be mostly a buyer of high quality dividend stocks, with solid competitive advantages. My holding period is forever, as long as the dividend is at least maintained. But, I do a thorough review every quarter to see if some stocks can be replaced with higher quality without sacrificing yield. Quality in this case means higher: estimated 5 year EPS growth; 10, 5, 3 and 1 year DGR; better Graham; or lower payout ratio. This review causes a turnover of 1 to 2 stocks per quarter. I Concentrate efforts on stocks which grow earnings and dividends and which provide outstanding total returns over time. For the most part, this means confining choices to the CCC list for security of dividends continuing and growing, and to limit downside swings in portfolio value. Diversify across sectors and geographic locations. Don’t buy illiquid stocks. CCC filters: 1. Est 5 year growth > 8 to 10% 2. NY growth > 8 to 10% 3. 5 yr DGR > 8 % 4. 1 yr DGR > 8% 5. D/E 3%), low payout stocks (
Ian Bezek worked for 3 years as an analyst at a New York-based hedge fund. He's currently living in Mexico, pursuing some entrepreneurial opportunities. He also assists Carden Capital with market analysis and strategic marketing.
Feel free to contact him regarding investments, writing, or speaking opportunities.
Over 30 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action. Background as a physician and pharmaceutical inventor and entrepreneur, however focus now is global and involves almost all economic categories.
INDEPENDENT Financial Advisor / Professional Investor- with over 30 years of navigating the Stock market's "fear and greed" cycles that challenge the average investor. Investment strategies that combine Theory, Practice and Experience to produce Portfolios focused on achieving positive returns over a period of time. Providing advice in helping to avoid the pitfalls and traps that wreak havoc on your portfolio with a focus on Income and Capital Preservation.
I manage the capital of only a handful of families and I see it as my number one job to protect their financial security. They don’t pay me to sell them investment products, beat an index, abandon true investing for mindless diversification or follow the Wall Street lemmings down the primrose path. I manage their money exactly as I manage my own so I don’t take any risk at all unless I strongly believe it is worth taking.
Blogging here on SA is part of my research. I write to find out what I think.
I invite you to join the family of satisfied clients send an e-mail :firstname.lastname@example.org
Investing has been my hobby for many years. I am an engineer in Silicon Valley.
I am not an investment adviser. None of my writings should be interpreted as investment advice. Please get an investment adviser and do your own due diligence before investing.
I hold a PhD in the field of epidemiology a masters degree in public health. My undergraduate training is in policy, economics and the sciences. I have utilized my training in employment with government, academia, private industry and to further analyze the fundamentals and technicals of all manner of companies in different sectors. Specifically, I like to trade growth companies, REITS, biotechnology/ pharmaceuticals, precious metals, blue chips and small-cap companies.
Each market day I get up at 530 am and begin working/analyzing data before my day job. I focus much on current events, earnings, and developments. I also work after market hours to cover after hours developments or interesting action during the day. I aim to conduct 2 analysis per business day, which helps me stay focused on my own finances.
I have been investing for about 10 years. I also enjoy trading short expiration options, and investing in stocks with 3-20 year horizons. I enjoy writing with Seeking Alpha to share my opinion and analyses. I am a large believer in the crowd source model championed by Seeking Alpha and believe every ounce of analysis and opinion should be considered when you invest your personal finances.
For a better mobile experience on Seeking Alpha click the top right menu icon on most browsers and select "request desktop site".
Would you do if your were already wealthy? If you could do whatever you wanted for your career, what would you want to do?
This is what I would do. This is my self-actualiziation. There is nothing like analyzing an inefficient sector of the market and calling out the failures.
I was trained in finance, but work in strategy. I invest very infrequently, and balance my portfolio once a year. I buy and hold hold indices and volatility ETFs. I trade a little bit on the side, but that's pure gambling, for fun.
You can follow me on Twitter and StockTwits, just search Nathan Buehler.
I have always had a passion for finance and investing. I enjoy and appreciate engaging with like minded individuals that inspire me to think beyond what is generally accepted. My investment experience spans almost ten years. The bulk of my knowledge has come from independent observation, research, patience, and perseverance. Most of my strategy is geared towards long term outlook with focuses on short term events or situations that create attractive opportunities.
I hope the articles presented here help you in your investment decisions. I value our discussions and look forward to professional dialogues. If I can ever help you with anything please contact me. Know you are always going to get a straight answer. If I don't know the answer I will either research it for you or tell you I don't know.
During the school year there may be a delay in my responses. Keep the feedback coming!
After having been in the investing world for more than 25 years from private banking and investment management to private and venture capital; I have pretty much "been there and done that" at one point or another. I am currently a silent partner for an RIA in Houston, Texas.
The majority of my time is spent analyzing, researching and writing commentary about investing, investor psychology and macro-views of the markets and the economy. My thoughts are not generally mainstream and are often contrarian in nature but I try an use a common sense approach, clear explanations and my “real world” experience in the process.
I am the Chief Editor of the REAL INVESTMENT REPORT, a weekly subscriber based-newsletter that is distributed nationwide. The newsletter covers economic, political and market topics as they relate to your money and life.
I also write a daily blog which is read by thousands nationwide from individuals to professionals at www.realinvestmentadvice.com.
Richard Zeits is an Oil & Gas industry analyst and consultant. His background includes fourteen years as Energy industry-focused investment banker, portfolio manager and senior investment analyst with bulge bracket firms in New York. Zeits Energy Analytics use elaborate proprietary analytics and data bases to provide in-depth industry research, market intelligence, and forecasting.
About our authors:
William A. Delwiche, CMT, CFA
Willie Delwiche is Baird’s Associate Investment Strategist. Before joining Baird in 1999, Willie worked briefly as a researcher at the Committee for Economic Development, a Washington, D.C., pro-business think tank. Willie received a BA in economics and in government and politics from the University of Maryland and an MA in economics from the University of Wisconsin – Milwaukee. He is a member of the Market Technicians Association and the American Economics Association.
Mary Ellen Stanek, CFA
Director of Asset Management
Mary Ellen Stanek, CFA, has 35 years of investment management experience. She currently serves as Managing Director and Director of Asset Management for Robert W. Baird & Co. and Chief Investment Officer of Baird Advisors. Additionally she serves as President of the Baird Funds. Previously she had served as President and CEO of Firstar Investment Research & Management Company.
Mary Ellen is responsible for the development and portfolio management of all proprietary asset management services. She co-manages several fixed income mutual funds as well as a number of taxable and tax-exempt portfolios. Mary Ellen is a member of The CFA Institute, the CFA Society of Milwaukee, the Greater Milwaukee Committee (Chair), Milwaukee 7 (Co-Chair), Tempo (past President) and Professional Dimensions.
Legendary investor Jeremy Grantham serves as Chairman of the Board of Grantham, Mayo Van Otterloo (GMO) and oversees quantitative products and investment strategies. Before GMO’s founding in 1977, Mr. Grantham was co-founder of Batterymarch Financial Management. Prior to helping found Batterymarch, he was a portfolio manager at Keystone Custodian Funds, a management consultant with Cresap McCormick & Paget, and an economist with Royal Dutch Shell. Mr. Grantham earned his undergraduate degree from the University of Sheffield (U.K.) and an M.B.A. from Harvard Business School.
Note: Mr. Grantham is not an active contributor to Seeking Alpha; rather, SA editors excerpt regularly from Mr. Grantham's public commentary.
Visit GMO (http://www.gmo.com/)
Hale Stewart spent 5 years as a bond broker in the late 1990s before returning to law school in the early 2000s. He is currently a tax lawyer in Houston, Texas. He has an LLM from the Thomas Jefferson School of Law in domestic and international taxation where he graduated Magna Cum Laude and is also a Chartered Asset Manager, Chartered Wealth Manager and Chartered Trust and Estate Planner from the American Academy of Financial Management. He is the author of the book US Captive Insurance Law. You can read him daily at the XE.com currency blog (http://community.xe.com/blog/xe-market-analysis).
Wasatch Advisors is the investment manager to the Wasatch Funds, as well as to separately managed institutional and individual portfolios. Wasatch Advisors pursues a disciplined approach to investing, focused on bottom-up, fundamental analysis to develop a deep understanding of the investment potential of individual companies. In making investment decisions, the portfolio managers employ a uniquely collaborative process to leverage the knowledge and skill of the entire Wasatch Advisors research team. Wasatch Advisors is an employee-owned investment advisor founded in 1975 and headquartered in Salt Lake City, Utah.
Have retired after having an over 20 year successful career as a Senior Financial Analyst for a Fortune 500 company where I performed due diligence on acquisitions, potential acquisitions as well as contributed to the completion of annual reports and preparing materials for the investment community. I am a bit rusty but I realized over the last 7 years that my analytical skills and niche in the the healthcare industry, specifically Biotechs, lends quite naturally to trading and covered calls. I am generally long, but the point of this business is to make money so I have developed my own method to take profits. Most recently I hold positions in $COR, $MAIN, $EXEL, $LXRX, $AKAO, $DYAX, $DVAX, $,GILD, $CELG, $LGND, $XON, $IRMD, $MITK, $ATVI, $AFFX, $TEVA,$PACB, $BPMC, $RLYP, $EGRX, $THLD, $ADXS, $O, $MITT,$T, $VZ, $VTR, $LMAT, $MO& $ED, $AAPL, $AMBA, $CRTO, $KR, $NKE, $DFS $SBUX just to name a few. I have been a consultant and consumer in the healthcare/biotech market for years and have been able to seek out growth opportunities and likely and successful buyout candidates with 15% of my portfolio dedicated to late-stage biotech specs and have achieved tremendous success, most recent examples are $SURG & $AFFX. Overall, however I do maintain a diversified portfolio and choose dividend paying stocks that offer both growth and income, specifically $MO, $TEVA, $BOH, $SBUX, $T, $HBI, were purchased during corrections providing outstanding yield & growth. I do utilize options very selectively to generate additional income, a strategy I that I find too risky during such volatility as we have experienced since the summer of 2015 through the drop we are currently experiencing currently. I am always re-evaluating my holdings, taking some profits, allowing for a larger cash position and taking advantage of the low prices of quality stocks. Biotech's seem to have been hit the hardest during these rotational corrections however if well researched, there is an excellent reward /risk profile and there is money to be made as long as spec investments are kept within your budget & there is a realistic understanding of the potential to lose it all. I both make and advise buys, as best as I can, to protect against the increased global instability & volatility this market is experiencing, regardless of the industry or company, that no one is immune from large losses so I don't invest what I can't afford to lose. Having had more than a few sleepless nights over the last 6-8 mos. in particular, my motto is if it keeps you up at night, rebalance!. I am always open to here other contributors' views whether or not they match my own, I believe we all have the ability to learn something valuable form each other.
Investment analyst concentrating on (and working in) non-U.S. markets. Favors bottom-up fundamental analysis but recognizes the necessity to apply a robust macro-overlay given linkages of markets, myriad crises and dynamic global economic environment. Sector concentration has been on those attached to emerging market themes, namely the commodities space.
As Chairman of Guggenheim Investments and Global Chief Investment Officer, Mr. Minerd guides the Firm’s investment strategies and leads its research on global macroeconomics. Prior to joining Guggenheim Partners, Mr. Minerd was a managing director at Morgan Stanley and Credit Suisse. He is involved in leadership roles at a number of civically-minded organizations, including Cedars-Sinai Medical Center and Strategic Partners Among Nations.
Senior Portfolio Manager and individual investor who started in high school and has been at it ever since. I have an MBA and have earned the right to use the Chartered Financial Analyst designation. I have worked in the business for over 15 years. My specialties are micro and small-cap value investing, fixed income closed-end funds, and macro analysis.
Curis, Inc. (CRIS) - NasdaqGM rated best investment going forward in Biotech for the remainder of 2014 and certainly for 2015.
Past Results - Achillion Pharmaceuticals, Inc. (ACHN) was issued a best investment rating on April 14, 2014 and it's hoped that on June 16, 2014 that investors locked in profit near the highs. The high that day was $8.05. The best investment rating was issued from the $2.70's area.
Athersys, Inc. (ATHX) - NasdaqCM In 2013 ATHX in the $1.60's area was issued a best investment notice. Followed up with several articles pointing out its potential. It's hoped investors took profit over $4 in early 2014. Today ATHX and its MultiStem is of high risk with one "no efficacy" phase II trial in 2014 reporting. For this reason ATHX is a buy only under $1.60 again today. This will limit downside to some degree if MultiStem fails again to show efficacy in a second phase II trial.
Other past calls were CLDX, ACUR and ALNY.
Portfolio Management 101 is led by CFA Charterholders with combined investment experience of over 25 years. The articles written by PM101 are intended to be informative and may contain opinions on the soundness of particular investments but should not be considered a recommendation for any particular investor. For this reason, we attempt to not only outline the reasons why we think an investment looks attractive but also highlight the risks that the investment entails. Investors should consider their own investment objectives and profile before using any of PM101 articles as the basis for investment.
Mark Krieger is an avid stock market trader dedicated to the following ideals: (1) Focus on high relative strength, (2) Buy low, sell high (3) Short high, cover low, (4) Go against the crowd, (5) It's all about the rules and discipline- hold them dear (6) Analyze the balance sheet-seek low debt,high cash and hidden value scenarios (7) Cut your losses short, let your gains run, (7) Don’t get emotional, (8) Follow the insiders- buy if they are buying, sell if they are selling (9) Be greedy when others are fearful and fearful when others are greedy.(10) Don't argue with the market unless you detect an inefficiency present-it is smarter than you are. In summary, some of these ideas might be construed as rather trite and overused, but consistent use of them pays off in the long run.
Mr. Krieger specializes in the food sector and is the originator of the "Basic Food Fund" index and the "Dirt Cheap Value Portfolio".Why the food sector? "everybody has to eat'!
He graduated from the University of Southern California with a BS in Business Administration with an emphasis in Corporate Finance. Mark resides in Cowan Heights, California with his wife, son and pug and is interested in mountain biking, gardening and reading.
The reports that I write are my personal research and opinions. They are not associated with any firm or organization, and are not intended to be taken as investment recommendations or advice. They combine my passions of economics, finance, writing and education, and are intended mostly as educational material. I attempt to write the articles in an easy to understand down to earth style in an effort to help others with their research. This is my effort to bring understandable and educational professional quality research to the public at large free of charge.
General Disclaimer for my Articles:
BS Business, Majored in Finance and Economics, Miami University
MA Economics w/ Managerial and International Emphasis, University of Oklahoma
Past: Economics and Finance Instructor at various Universities
Past: Mutual Fund Portfolio Manager of Family of Mutual Funds
Past: CIO of Mid-Sized Investment Management Firm
Professional: CFA Charterholder
Please note that the content of this site should not be construed as investment advice, nor do the opinions expressed necessarily reflect the views of CFA Institute.
I look for a change in sentiment that precedes the change in trend. Moments of "lag" in sentiment can provide superb entry points into special situations at a discount; and obversely, manic enthusiasm can provide an opportunity to go short.
I research the fundamentals, know what I am getting into, and go long or short accordingly. Technical studies of the market are also an active part of my trading. I have invested for 22 years.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
Bluford (Blu) Putnam has served as Managing Director and Chief Economist of CME Group since May 2011. He is responsible for leading economic analysis on global financial markets by identifying emerging trends, evaluating economic factors and forecasting their impact on CME Group and the company's business strategy. He also serves as CME Group's spokesperson on global economic conditions and manages external research initiatives.
Prior to joining CME Group, Putnam gained more than 35 years of experience in the financial services industry with concentrations in central banking, investment research and portfolio management. He most recently served as Managing Partner for Bayesian Edge Technology & Solutions, Ltd., a financial risk management and portfolio advisory service he founded in 2000. He also has served as President of CDC Investment Management Corporation and Managing Director and Chief Investment Officer for Equities and Asset Allocation at the Bankers Trust Company in New York. His background also includes economist positions with Kleinwort Benson, Ltd., Morgan Stanley & Company, Chase Manhattan Bank and the Federal Reserve Bank of New York.
Putnam holds a bachelor's degree in liberal arts from Florida Presbyterian College (later renamed Eckerd College) and a Ph.D.in economics from Tulane University. He has authored five books on international finance, as well as many articles that have been published in academic journals and business publications.